Cardiff Oncology, Inc. (NASDAQ:CRDF) Q1 2023 Earnings Call Transcript [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Cardiff Oncology, Inc. (CRDF)
Company Research
Source: Yahoo! Finance
Cardiff Oncology, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter ( see the details here Operator: Welcome to the Cardiff Oncology First Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]. Please be advised that today's conference is being recorded. I would now like to turn the conference call over to Kiki Patel of Gilmartin Group. Please go ahead. Kiki Patel: Thank you, operator. Joining us on the call today from Cardiff Oncology are Chief Executive Officer, Mark Erlander, and Chief Financial Officer, Jamie Levine. During this conference call, management will make forward-looking statements including, without limitations, statements related to guidance, results, and the timing of the data readouts for onvansertib clinical trials. These forward-looking statem
Show less
Read more
Impact Snapshot
Event Time:
CRDF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRDF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRDF alerts
High impacting Cardiff Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CRDF
News
- Cardiff Oncology to Present at the Jefferies Healthcare ConferenceGlobeNewswire
- Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data [Seeking Alpha]Seeking Alpha
- Cardiff Oncology to Present at Upcoming Investor Conferences in MayGlobeNewswire
- Cardiff Oncology, Inc. (NASDAQ: CRDF) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.MarketBeat
- Cardiff Oncology First Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
CRDF
Earnings
- 5/2/24 - Beat
CRDF
Analyst Actions
- 5/6/24 - HC Wainwright
CRDF
Sec Filings
- 6/20/24 - Form 8-K
- 6/17/24 - Form DEFA14A
- 6/3/24 - Form DEFA14A
- CRDF's page on the SEC website